Added to YB: 2025-06-17
Pitch date: 2025-06-14
INMB [neutral]
INmune Bio, Inc.
-76.48%
current return
Author Info
Ahead of the Curve focuses on identifying and owning great small cap companies. Sign up for the newsletter.
Company Info
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Market Cap
$50.5M
Pitch Price
$7.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.44
P/E
-0.76
EV/Sales
351.78
Sector
Biotechnology
Category
special_situation
Taking Stock, Recalibrating, and Signing Off: Current Portfolio - INmune Bio, Inc.
INMB (holding update): Clinical-stage biotech targeting innate immune system for neurodegenerative diseases/cancer. June Phase II results for XPro (Alzheimer's) could halve price if bad or drive 5-10x upside if good. Market pricing low odds vs experts' ~50%. Management invested own money. Binary bet with lopsided risk-reward.
Read full article (2 min)